High Prevalence of Hepatitis B in People With HIV in the MWCCS, 2018–2024
Authors:
- Maria F Sanes GuevaraMGMaria F Sanes Guevara
- Ken S HoKHKen S Ho
- Anandi N ShethASAnandi N Sheth
- Andrew EdmondsAEAndrew Edmonds
- Audrey L FrenchAFAudrey L French
- David B HannaDHDavid B Hanna
- Heather KingHKHeather King
- Jennifer C PriceJPJennifer C Price
- Maria L AlcaideMAMaria L Alcaide
- Matthew J MimiagaMMMatthew J Mimiaga
- Michael AugenbraunMAMichael Augenbraun
- Michael PlankeyMPMichael Plankey
Open Access
- 2 June 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag346
Abstract
Background: This study aimed to examine the prevalence of hepatitis B virus (HBV) in people with HIV (PWH) undergoing contemporary antiretroviral therapy and people without HIV and to understand the risk factors in people with HIV/HBV coinfection. This retrospective cross-sectional study included 5238 participants with HIV or at risk for HIV acquisition across 13 US sites in the MACS/WIHS Combined Cohort Study (Multicenter AIDS Cohort Study / Women Interagency HIV Study) between January 2018 and December 2024. Methods: The primary outcome was the prevalence of HBV infection and HIV/HBV coinfection. We defined a positive HBsAg (surface antigen) as chronic HBV infection, a negative HBsAg and positive anti-HBV core antibody as recovered infection, and a negative HBsAg and negative anti-HBV core antibody as never infection. The prevalence of chronic and recovered HBV infection was described in different risk groups. Results: In this cohort, the overall prevalence of chronic HBV was 2.4%, and HIV/HBV coinfection was 3.0% among PWH. Current and prior HBV infection was more common in men, and the prevalence of prior HBV increased with age. As compared with the other 2 groups, PWH with chronic HBV infection had lower CD4+ T-cell counts (567 vs 651 and 689 cells/µL), CD4+ T-cell nadirs (210 vs 245 and 258 cells/µL), and HIV viral suppression rate (71.7% vs 82.3% and 83.7%). Among PWH who never had HBV infection, 40.6% lacked seroprotection against HBV. Conclusions: HBV is still prevalent in PWH. HBV coinfection was associated with lower CD4+ T-cell counts and viral suppression rate in PWH. The low seroprotection rate in those without HBV underscores the need for improved screening and immunization.Keywords
Funding Information
- MWCCS
- Atlanta
- Clinical Research Site (U01-HL146241)
- Baltimore CRS (U01-HL146201)
- Bronx CRS (U01-HL146204)
- Brooklyn CRS (U01-HL146202)
- Data Analysis and Coordination Center (U01-HL146193)
- Chicago–Cook County CRS (U01-HL146245)
- Chicago–Northwestern CRS (U01-HL146240)
- Los Angeles CRS (U01-HL146333)
- Metropolitan Washington CRS (U01-HL146205)
- Miami CRS (U01-HL146203)
- Northern California CRS (U01-HL146242)
- Pittsburgh CRS (U01-HL146208)
- University of Alabama at Birmingham–Multiple Sclerosis Center CRS (U01-HL146192)
- University of North Carolina CRS (U01-HL146194)
- National Heart, Lung, and Blood Institute
- Eunice Kennedy Shriver
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute on Aging
- National Institute of Dental and Craniofacial Research
- National Institute of Allergy and Infectious Diseases
- National Institute of Neurological Disorders and Stroke
- National Institute of Mental Health
- National Institute on Drug Abuse
- National Institute of Nursing Research
- National Cancer Institute
- National Institute on Alcohol Abuse and Alcoholism
- National Institute on Deafness and Other Communication Disorders
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Minority Health and Health Disparities
- Office of AIDS Research
- National Institutes of Health (UL1-TR000004)
- UCSF CTSA (UL1-TR003098)
- JHU ICTR (UL1-TR001881)
- Clinical and Translational Science Institute, University of California, Los Angeles (P30-AI-050409)
- Atlanta CFAR (P30-AI-073961)
- Miami CFAR (P30-AI-050410)
- Center for AIDS Research, University of North Carolina at Chapel Hill (P30-AI-027767)
- Center for AIDS Research, Heersink School of Medicine, University of Alabama at Birmingham (P30-MH-116867)
- Miami CHARM (UL1-TR001409)
- DC CTSA (KL2-TR001432)
- DC CTSA (TL1-TR001431)
- DC CTSA
This publication has 13 references indexed in Scilit:
- Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practiceClinical Infectious Diseases, 2025
- Monitoring and risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis BAIDS, 2025
- HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine NonresponseJAMA, 2025
- Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature ReviewViruses, 2021
- Characteristics of the MACS/WIHS Combined Cohort Study: Opportunities for Research on Aging With HIV in the Longest US Observational Study of HIVAmerican Journal of Epidemiology, 2021
- HIV Outcomes in Hepatitis B Virus Coinfected Individuals on HAARTJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort StudyThe Journal of Infectious Diseases, 2013
- Immunological and virological responses to combined antiretroviral therapy in HIV/hepatitis B virus-coinfected patients from a multicenter cohortAIDS, 2012
- Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007†Journal of Viral Hepatitis, 2010
- HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)The Lancet, 2002